Diagnosed with primary hepatic carcinoma
Conditions
Interventions
A:umbilical cord blood CIK cell infusion + TACE
Sponsors
The 105th Hospital of PLA
Eligibility
Sex/Gender
All
Age
26 Years to 78 Years
Inclusion criteria
Inclusion criteria: (1) The diameter of tumor in all patients is between 2cm 10cm, Swelling limited to liver, no portal cancerous thrombus and distant metastasis; (2) The grade of liver function is Child - Pugh A or B, KPS >=7O, and expected survival time is more than 6 months; (3) patients and relatives signed CIK treatmen consent, and received approval of the hospital ethics committee.
Exclusion criteria
Exclusion criteria: 1) history of cardiovascular disease: congestive heart failure> New York Heart Association (NYHA) II level, patients with unstable angina (angina symptoms occur at rest) or new onset of angina (the last 3 months of onset) or recent myocardial infarction within 6 months of patients; 2) poor body condition, cachexia; Or in combination with other fatal diseases; 3) laboratory tests of liver function ALT, AST 2.0 times higher than the upper limit of normal; Or renal TBIL, Bun more than 1.0 times the upper limit of normal, or Cr above the normal upper limit; 4) active infection; 5) patients pregnant or lactating women; 6) Now, the recent (-4 weeks, 1 day before) or will join another clinical drug trial research; 7) The researchers believe that other circumstances can not be selected: If the impact into the group of patients to participate in or completion of clinical studies (such as mental illness, substance abuse, HIV infection, etc.), or affect the results of the analysis of clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical effect Evaluation: assess short-term effect: disease control rate DCR (CR+PR+SD);Progression-Free Srvival, PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| immunology indeces; | — |
Contacts
Public ContactCongxin Chen
Outcome results
None listed